OptiBiotix Health PLC Investor evening
May 02 2019 - 2:00AM
RNS Non-Regulatory
TIDMOPTI
OptiBiotix Health PLC
02 May 2019
OptiBiotix Health plc
("OptiBiotix" or "the Company")
Investor evening
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing products to tackle obesity, high cholesterol and
diabetes, announces that Stephen O'Hara, CEO of Optibiotix, will be
presenting at an investor evening hosted by Turner Pope Investments
Ltd ("TPI") on Monday, 13 May 2019. The event will be held in the
City of London and will commence at 5pm.
To register your interest and obtain further details, please
contact TPI on info@turnerpope.com or call 0203 621 4124.
No new material or trading information will be provided.
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook below
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
About OptiBiotix Health PLC - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which
modify the human microbiome - the collective genome of the microbes
in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial
strains, compounds and formulations, which modulate the human
microbiome and can be used as food ingredients and supplements or
active compounds for the prevention and management of human
diseases, examples of which include obesity, cholesterol and lipid
distribution, diabetes, and skin health.
OptiBiotix has established a pipeline of microbiome modulators
that can impact on lipid and cholesterol management, energy
harvest, appetite suppression, and skin health. The development
pipeline is fuelled by its proprietary OptiScreen(R) and
OptiBiotic(R) platform technologies designed to identify metabolic
pathways and compounds that impact on human physiology and bring
potential health benefits. These platforms are applicable across a
wider range of other human diseases.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRASSSFSFFUSELI
(END) Dow Jones Newswires
May 02, 2019 02:00 ET (06:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024